| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | FORM S-3 |
| 12 Nov 2026 | FORM 10-Q |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | FORM S-8 |
| 12 Aug 2026 | FORM 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year |
| 24 Jun 2026 |
Form 4: Wan Mark A, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 24 Jun 2026 |
Form 4: Todisco Joseph, Director
Received 5,100 shares as a grant or award · Granted 30,700 Director Stock Option (right to buy) |
| 24 Jun 2026 |
Form 4: Jain Abhinav, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 24 Jun 2026 |
Form 4: Hoffman Stephen J, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 24 Jun 2026 |
Form 4: Broadfoot Jill Marie, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 24 Jun 2026 |
Form 4: Bozilenko Marina, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 24 Jun 2026 |
Form 4: Adams Adrian, Director
Received 5,100 shares as a grant or award · Granted 30,700 Stock Option (Right to Buy) |
| 23 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) any Returning Shares will beco... |
| 21 May 2026 |
Form 4: Aslam Shakil, Chief Medical Officer
Gave up 4,518 shares to cover exercise price or tax ($3.72K) |
| 15 May 2026 | SCHEDULE 13G/A |
| 13 May 2026 | FORM 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
NEPHRO CRRT clinical study expected to be completed this year |
Loading...